Many great companies have their roots in academia — especially those operating in deeptech and life sciences. According to Dealroom, there are now roughly 14,000 active private university spinouts originating from Europe, and 226 of them were launched between 2025 and 2026. They account for around 40% of all new deeptech and life sciences startups since 2019 and are now worth close to $400 billion. In other words, a significant share of Europe’s most technically advanced companies begin inside universities.
How spinouts get funded
In recent years, VC funding that goes into spinouts has accelerated sharply, as by Q3 2025, these companies have raised $7.9 billion — more than doubling the pre-pandemic levels.
But the most interesting metric to look at is the capital efficiency — many spinouts reach $25–35 million valuations on just $5–8 million raised — driven by proprietary research and defensible IP.
More often than not, things like patents, strong R&D background, and lab validation are already in place before the company raises its first institutional round.
Public funding also plays an important role here. Programs like Horizon Europe, with a budget exceeding €90 billion, alongside national R&D spending of 2–3% of GDP across many European countries, effectively subsidize the earliest and riskiest stages of innovation. By the time VCs enter, much of the technical risk has already been absorbed by public capital. This is particularly visible in climate engineering, where long development cycles and high upfront costs align with academic research environments.
When it comes to VC funds, new ones are being built specifically to tap into university talent and IP before it hits the broader market. From recent examples, PSV Hafnium closed an oversubscribed €60 million debut fund focused on Nordic deeptech, while U2V raised a similar-sized vehicle to back European technical universities' spinouts. These firms are extending a model established by earlier players such as Cambridge Innovation Capital and Oxford Science Enterprises, which built tightly integrated pipelines between universities and venture capital.
Deeptech is taking the lead
For many years, European spinouts were mostly focused on biotech and pharmaceuticals, but lately, deeptech has taken the lead — around 65% of photonics startups and 60% of quantum companies originate from academia.
Together with life sciences, deeptech now represents over 84% of the total value created by European spinouts, with a combined valuation approaching $400 billion.
Their value has grown sevenfold over the past decade, and the pipeline continues to expand from roughly 100 new companies per year in the early 2000s to more than 500 annually since 2015. There are also currently around 76 unicorns in these fields.
In biotech, academia has created some of the most prominent companies in the field, including BioNTech (public, originated from Johannes Gutenborg University in Mainz), Abcam (acquired and valued at $5.7 billion, originating from Cambridge), and Ablynx (from Flanders Institute for Biotechnology (VIB) & Vrije Universiteit Brussel, acquired at a valuation of $4.3 billion)
Other important sectors include energy, climate, health, and increasingly AI, data infrastructure, and space — those verticals are accelerating at the biggest pace.
Almost all of these spinouts operate as B2B businesses, often developing industrial or infrastructure technologies. Consumer-facing startups are largely absent, mirroring Europe’s academic strengths in physics, chemistry, and engineering, alongside a weaker tradition of university-driven consumer ventures compared to the US.
The UK leads in spinout creation
In Europe, spinout creation tends to cluster around a small number of universities and national ecosystems. The UK dominates, with the University of Oxford and the University of Cambridge taking the first two spots as leading hubs, with three additional UK institutions in the top ten. This concentration translates directly into value: the UK leads Europe in total spinout value creation, ahead of Germany, France, and Switzerland.
On a per capita basis, however, it is Switzerland that is taking the lead — it has a smaller, but more concentrated and intense system, with institutions like ETH Zurich, EPFL, and the University of Zurich.
The biggest bottleneck is scaling
The biggest threat to Europe’s spinouts is the late-stage funding gap. At the early stage, 86% of capital comes from inside Europe. But for late-stage rounds, $100 million+, nearly 50% of the money comes from outside Europe, mostly the US. What is more, because Europe lacks a strong IPO market, mergers and acquisitions are at an all-time high. US acquirers have bought nearly $24 billion worth of European spinouts since 2019.
Dealroom's data says, this is the core problem: European governments fund the expensive, risky research, but US mega-funds provide the scaleup capital, and in the end, the US tech giants buy the final product.
